Kelvin Lee is an Oncology physician. ClinicalTrials.gov lists 4 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1701 N Senate Blvd
Indianapolis, IN 462021239
Telephone
888-484-3258Provider last certified this registry record 14 Mar 2025.
Clinical trials
- Lenalidomide With or Without Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Sponsor: Roswell Park Cancer Institute
- Fludarabine and Thalidomide in Treating Patients With Newly Diagnosed Chronic Lymphocytic Leukemia
Sponsor: Roswell Park Cancer Institute
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Janssen Biotech, Inc.Program year20251 payment
- Intercept Pharmaceuticals, Inc.Program year20251 payment
- GlaxoSmithKline, LLC.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
65%Thalidomide Analog44.4%Lenalidomide55%Revlimid45%Part D<11 patientsProteasome Inhibitor12.2%Ninlaro100%Part D<11 patients+ 1 more class in this area
Dermatology
22.8%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor22.8%Acyclovir100%Part D≥12 patientsSensory organs
6.1%Corticosteroid6.1%Dexamethasone100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
3 NIH research awards on record, funded 2020–2026 per NIH RePORTER. The latest:
- Novel pro-survival mechanisms of PIM2 in multiple myeloma
Indiana University Indianapolis
FY2026$571,063R01CA272852 - Indiana University Melvin and Bren Simon Comprehensive Cancer Center Support Grant
Indiana University Indianapolis
FY2025$2,845,630P30CA082709 - Novel pro-survival mechanisms of PIM2 in multiple myeloma
Indiana University Indianapolis
FY2025$571,063R01CA272852
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”